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Gonorrhoea, caused by the Gram-negative bacterium Neisseria 
gonorrhoeae and first identified in 1879 by Albert Neisser (1855 
- 1916), is one of the oldest infections known to man and is 
efficiently spread through unprotected sexual intercourse. 
Primary sites of infection include the urethra, the endocervix, 
the anorectum, the pharynx, the conjunctivae and the vagina 
in pre-pubescent girls. Complications were highly prevalent in 
the pre-antibiotic era and, to a lesser extent, still occur today 
as a result of delayed access to effective, or dispensing of 
inappropriate, antibiotics.
The last 60 years have witnessed the introduction of 
effective chemotherapy and, since then, the gonococcus has 
demonstrated remarkable powers of adaptation.1  Changes 
in the clinical features, patterns of transmission, and the 
development of both chromosomal and plasmid-mediated 
antibiotic resistance have been described. The development of 
antibiotic resistance among gonococci continues to threaten the 
success of the syndromic management in many of the world’s 
poorest regions where the prevalence of gonorrhoea is often 
highest.
The pre-antibiotic era
Gonorrhoea was a major cause of morbidity and mortality 
in the pre-antibiotic era. Men with acute urethritis and its 
complications appeared to constitute the main clinical load for 
physicians, although gonorrhoea was also the major cause of 
pelvic inflammatory disease (PID) in women. 
Acute urethritis was treated using anterior urethral irrigation 
with warm potassium permanganate (1/3 000) twice daily 
for 2 weeks.2  The apparatus for urethral irrigation had two 
levels for the reservoir, a lower level for anterior urethritis and 
a higher level for posterior urethritis. Over-zealous use of the 
apparatus though raising of the reservoir too high sometimes 
resulted in iatrogenic epididymo-orchitis and prostatitis.  
Complications such as acute retention of urine were 
sometimes relieved by the administration of a soap and water 
enema, the administration of laudanum orally or further hot 
baths. Urethral or suprapubic catheterisation was undertaken 
for those men who remained in urinary retention. Following 
resolution, the patient was often urethroscoped to search for 
persistent glandular infections. Numerous types of urethral 
dilators were designed to deal with urethral strictures in the 
anterior and posterior urethra. 
During World War I, when gonorrhoea was particularly 
common among the troops, the British Army introduced 
tents containing irrigation equipment in France – the British 
soldiers humorously nick-named the potassium permanganate 
irrigations ‘pinky panky’. By 1917, prophylactic packets, 
containing calomel ointment to apply to the genitals, a tube 
of argyrol to apply to the urethra after sexual intercourse and 
the occasional condom, were given to soldiers in an attempt to 
prevent the development of gonorrhoea after sexual exposure. 
By World War II, the military establishment had come to 
appreciate the importance of male condoms and made these 
widely available for troops. Post-coital treatment centres 
were also set up in many locations, but the breakthrough in 
the management of gonorrhoea came with the discovery of 
sulphanilamide, the first anti-gonococcal antibiotic.  
Antibiotic-resistant gonococci – past, present and future
David A Lewis
Sexually Transmitted Infections Reference Centre, National Institute for 
Communicable Diseases; Department of Internal Medicine, University of the 
Witwatersrand; and Institute of Infectious Disease and Molecular Medicine, 
University of Cape Town
David A Lewis, FRCP (UK), PhD, DTM&H
Gonorrhoea remains one of the commonest STIs from 
a global perspective and, left untreated or treated 
inadequately, may result in serious complications such 
as epididymo-orchitis and pelvic inflammatory disease 
and their adverse sequelae. Since the introduction of 
sulphonamides in the 1930s, the gonococcus has shown 
itself to be a master of adaptability and has acquired a 
number of chromosomal and plasmid-mediated antibiotic 
resistance mechanisms. The continual development and 
spread of in vivo resistant strains has resulted in several 
key changes in recommended therapy for gonorrhoea over 
past decades. The recent emergence of quinolone resistance 
among gonococci isolated in South Africa now threatens 
to undermine the success of the syndromic management 
approach to date. Within South Africa, there is now 
an urgent need to change first-line therapy away from 
ciprofloxacin to a third-generation cephalosporin.  With 
the lack of new therapeutic agents on the horizon, a future 
with multi-drug therapy as the main management strategy 
for antibiotic-resistant gonorrhoea looks inevitable. The 
importance of condoms in the prevention of gonococcal 
transmission should not be under-estimated and STI 
prevention efforts should be increased. 
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Sulphonamides
In 1935, Gerhard Domagk reported that ‘Prontosil’ was 
curative against β-haemolytic streptococci in animals and, 
subsequently, humans. Prontosil released sulphanilamide, 
a sulphonamide that was easy to manufacture. The first 
studies using sulphanilamide to treat gonorrhoea were 
performed in Germany, the UK and the USA in 1937. Cure 
rates for gonorrhoea were reported in the 80 - 90% range and 
allowed the disuse of urethral irrigation. By 1944, however, 
many gonococci had become resistant to sulphanilamide and 
treatment failure was observed in over 30% of patients.3  By the 
end of the 1940s, the prevalence of sulphonamide resistance in 
vitro had risen to approximately 90%.
Penicillins
Cecil Paine, a Scottish doctor, was reportedly the first person 
to use penicillin to treat gonococcal infection. In 1930, he 
successfully treated gonococcal ophthalmia neonatorum with a 
crude extract of Penicillium notatum. Penicillin was first used to 
treat gonococcal urethritis in 1943 in American troops fighting 
in World War II. Clinical cure rates in excess of 95% were 
observed and many believe that the ‘magic bullet’ had arrived 
for effective long-term control of gonorrhoea. 
By 1958, however, chromosomal resistance to penicillin 
in gonococci was described although it could be overcome 
by increased therapeutic dosage.4  In the ensuing years, 
chromosomal resistance was associated with increasing 
clinical treatment failure even with the administration of 
higher penicillin dosage. Chromosomal resistance is the result 
of multiple mutations in several key loci, for example the 
penA, penB and mtr genes, which individually cause modest 
rises in the minimum concentration of penicillin required to 
inhibit gonococcal growth in vitro (the minimum inhibitory 
concentration, or MIC); however, mutations in all three genes 
may result in a 120 times increase in the MIC of penicillin 
(Table I). Mutation at the penA locus affects resistance to β-
lactam antibiotics only, whereas mutations at the penB and 
mtr loci are pleiotropic. In addition, mutations in the pem gene 
induce further increases in resistance to penicillin by modifying 
the expression of the penA, penB and mtr genes.
Plasmid-mediated high-level resistance to penicillin was 
first described in a gonococcal strain isolated in the UK, 
with epidemiological links to West Africa.5  Plasmid analysis 
identified a 3.2 MDa ‘African’ plasmid. Almost at the same 
time, a penicillinase-producing N. gonorrhoeae (PPNG) strain 
was isolated in the USA in a soldier returning from the 
Phillipines due to bacterial carriage of the 4.4.MDa ‘Asian’ 
plasmid.6  Although there were phenotypic differences 
between these two plasmid-carrying strains, the plasmids 
possessed identical genes encoding a TEM-1 type β-lactamase 
and differed simply by a 2.1 kb deletion (Table II). Since their 
original descriptions, the host ranges of both the ‘African’ 
and ‘Asian’ plasmids have extended to other gonococcal 
auxotypes, and the ‘African’ plasmid has been found in 
association with the 24.5 MDa conjugative plasmid. Further 
penicillinase-producing plasmids have been identified in recent 
years, including the 2.9 MDa ‘Rio’ plasmid, the 3.05 ‘Toronto’ 
plasmid, the 4.0 MDa ‘Nimes’ plasmid and the 6.5 MDa ‘New 
Zealand’ plasmid. Today, penicillins can no longer be relied 
Table II. Characteristics of the African and Asian plasmids and their initial host strains
Plasmid name    ‘African’   ‘Asian’
Epidemiological link   West Africa  The Phillipines
Phenotype (auxotype)   Arginine-requiring  Proline-requiring or wild type
Plasmid size     3.2 MDa (5.1 kb)  4.4 MDa (7.2 kb)
Tetracycline susceptibility   Yes   No
24.5 MDa conjugative plasmid  Absent   Present
Table I. Some of the key effects of mutations in the penA, penB, mtr and pem genes resulting in chromosomal resistance to 
penicillin
Gene      Effect of mutation
penA  • 4 - 8-fold increase in penicillin MIC
  •  Lowered affinity of penicillin for penicillin-binding protein 2 (PBP-2) due to insertion of an asparagine molecule at 
amino acid position 345
  • Shift in target to penicillin-binding protein 1 (PBP-1)
  • Decrease in o-acetylation of peptidoglycan
penB  • 4-fold increase in penicillin and tetracycline MICs when occurring with a mutation in the mtr gene
mtr  • Low-level resistance to several antibiotics (penicillin, erythromycin, tetracycline)
  • Resistance to dyes, detergents and fatty acids
  • Altered cell envelope with decreased cell permeability
  • Increased amounts of a 52 kDa outer membrane protein
pem  • Modifies the expression of the penA, penB and mtr genes
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upon to produce effective cure of gonorrhoea in many parts of 
the world, especially where local microbiological surveillance 
data are lacking.
Tetracyclines
Chlortetracycline and oxytetracycline, the first members of the 
tetracycline group of antibiotics, were discovered in the late 
1940s. Doxycycline, often used in combination with an anti-
gonococcal agent in STI syndromic therapy to cover chlamydial 
infections, appeared slightly later as a semi-synthetic product. 
The tetracyclines inhibit bacterial growth primarily by 
inhibiting protein synthesis at the level of the ribosome. 
Since the introduction of tetracycline therapy for the 
treatment of gonorrhoea and/or chlamydial infection, 
gonococci that exhibit a low level of resistance to this drug 
have been isolated with increasing frequency.7  Mutations 
in the penB and mtr chromosomal loci may together result 
in reduced susceptibility to tetracycline through decreased 
permeability (Table I). However, the main mechanism of 
gonococcal resistance to tetracyclines involves ribosomal 
protection whereby tetracyclines no longer bind efficiently to 
the bacterial ribosome. This is the case for resistance mediated 
by mutations in the chromosomal tet gene as well as for the 
high-level tetracycline resistance in gonococci, mediated 
through acquisition of a 25.2 MDa conjugative plasmid which 
contains the TetM determinant. 
The first report of high-level plasmid-mediated tetracycline- 
resistant N. gonorrhoeae (TRNG) arose in the US in 19868 
although they were first detected in the Netherlands in 1985.9  
Based on auxotype and phenotype, the Dutch TRNG had 
different phenotypes to those isolated in North America. The 
plasmids also appear different in that all the Dutch TRNG 
25.2 MDa plasmids belong to one restriction map type (the 
‘Dutch’ type) which is closely related to the gonococcal 24.5 
MDa plasmid. In contrast, plasmids from the USA and the UK 
belonged to a different restriction map type (the ‘American’ 
type) and appeared to be very different to the 24.5 MDa 
conjugative plasmid of N. gonorrhoeae. 
Spectinomycin
Spectinomycin was developed and marketed specifically for 
the treatment of gonorrhoea. Although effective in many cases, 
the drug’s clinical efficacy is limited by a narrow effective MIC 
range. Resistance was first described in 1973 and is due to a 
mutation in the spc locus which decreases the sensitivity of the 
30S ribosomal subunit to spectinomycin. With the rapid rise in 
PPNG and failure of penicillin to effectively cure gonorrhoea in 
its troops, the US military introduced spectinomycin in Korea 
in 1981. By 1985, the prevalence of spectinomycin resistance 
had risen from 0% to 7%, and by 1987 its use was discontinued 
as resistance was detected in more than 50% of gonococcal 
isolates.10  
Macrolides 
Macrolides such as erythromycin and azithromycin may treat 
gonococcal infection, although their use may be associated 
with the rapid development of resistance.11  The single 2 g oral 
dose of azithromycin required to effectively treat gonorrhoea 
is associated with unacceptably common gastrointestinal 
side-effects and it is therefore not recommended by the World 
Health Organization (WHO). The presence of a self-mobile 
rRNA methylase gene(s) erm F, or erm B and erm F, has been 
shown to be responsible for macrolide resistance in some 
strains of N. gonorrhoeae.12  In addition, gonococci can employ 
both the MacA-MacB and MtrC-MtrD-MtrE ABC efflux 
systems to become resistant to macrolides.13   
Quinolones
Nalidixic acid was the first quinolone to be used in the clinical 
setting but is restricted to the treatment of uncomplicated 
Gram-negative urinary tract infection.   The advent of the 
fluoroquinolones, including ciprofloxacin, resulted in agents 
with 100 times greater antibacterial potencies when compared 
with nalidixic acid. Fluoroquinolones have a fluorine atom at 
position 6 of the quinolone structure, but is it not clear how 
this enhances antibacterial potency. The 3-carboxylate and 
4-carbonyl groups of the quinolone moiety are important 
for therapeutic action since they bind DNA gyrase, the main 
intracellular target of the fluoroquinolones. DNA gyrase 
catalyses the negative supercoiling of DNA in bacteria and 
consists of two A subunits, encoded by gyrA, and two B 
subunits, encoded by gyrB. The A subunits are involved in 
DNA breakage and the B subunits in ATP hydrolysis required 
for DNA supercoiling. It is believed that fluoroquinolones 
interrupt the DNA breakage and resealing steps of the catalytic 
process.
Ciprofloxacin was introduced to treat gonorrhoea in the early 
1980s. Until the last decade, ciprofloxacin retained excellent 
in vitro activity against N. gonorrhoeae strains from around the 
world with a MIC values from 0.0005 mg/l to 0.03 mg/l (mean 
MIC90 ≤0.002 mg/l). Ciprofloxacin had the extra advantage 
of high efficacy in the treatment of pharyngeal infections, 
which are important anatomical sites in the transmission of 
gonorrhoea in certain groups, for example among men who 
have sex with men (MSM). 
From the early 1990s onwards, in part due to excessive 
use and poor control over antibiotic prescribing, increasing 
reports of quinolone-resistant N. gonorrhoeae (QRNG) appeared 
throughout much of Asia, the Pacific region, Europe and 
the USA. Annual surveillance in the UK demonstrated the 
appearance of gonococcal strains with reduced susceptibility 
to ciprofloxacin before the emergence of clinically significant 
ciprofloxacin resistance.14  The world’s first 250 mg single dose 
ciprofloxacin treatment failure for gonorrhoea was reported 
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in London in 1990 and other reports soon followed.15  These 
initial strains, with reduced susceptibility, had mutations in the 
gyrA genes and MICs were in the region of 0.06 - 0.25 mg/l. 
The WHO, the Centers for Disease Control and Prevention 
(Atlanta) and the UK’s Public Health Laboratory Service 
subsequently recommended the use of a single 500 mg dose of 
ciprofloxacin to treat gonorrhoea. 
More recently, global clinical failures have been observed 
with the 500 mg dose and the MICs from post-treatment 
isolates have been shown to be 1 mg/l or above. Many 
gonococci with higher MICs, in the region of 2 mg/l or 
above, were found to have mutations in both the gyrA and 
parC genes. The parC gene encodes for one of the subunits 
of topoisomerase IV, another enzyme involved in DNA 
supercoiling. Characteristic point mutations, associated with 
the development of ciprofloxacin resistance, occur in both 
the gyrA and the parC genes in so-called quinolone resistance 
determining regions (QRDRs).16  
By the mid-1990s, QRNG were highly prevalent in the 
WHO’s Western Pacific and South East Asian Regions. 
Surveillance activities undertaken in 12 European countries in 
2004, by the newly formed European Surveillance of Sexually 
Transmitted Infections (ESSTI) network, revealed an average 
QRNG prevalence of 31% in 2004.17  By contrast, up until 2003, 
little or no resistance was reported from Africa and South 
America, in part due to a lack of established microbiological 
surveillance systems. 
The sudden appearance of ciprofloxacin-resistant gonorrhoea 
in South Africa was first reported among isolates tested in 
Durban in 2003.18  A collaborative national survey undertaken 
in 2004 as part of South Africa’s newly established National 
STI Surveillance Programme, and co-ordinated by Professor 
Hendrik Koornhof at the National Institute for Communicable 
Diseases’ STI Reference Centre in Johannesburg, demonstrated 
marked variation in ciprofloxacin resistance within the 
country:19 24% in Durban, 11% in Johannesburg, 10% in 
Umtata, 8% in Pietermaritzburg, 7% in Cape Town and 0% in 
Pretoria (Fig. 1). Since the 2004 survey, unpublished reports of 
further rises in ciprofloxacin resistance have been reported in 
Durban (44%, 2006), Johannesburg (33%, 2007) and Cape Town 
(28%, 2007). 
Cephalosporins
At the current time, third-generation cephalosporins remain 
the only class of antibiotic that can reliably treat gonorrhoea. 
These agents are intrinsically resistant to the effects of β-
lactamase, and have high potency and a relatively long half-
life. Intramuscular ceftriaxone has been established as a reliable 
treatment for gonorrhoea although cefixime and cefpodoxime 
have been recommended as single dose oral alternatives. For 
all the cephalosporins, data are less impressive regarding 
the efficacy of therapy for eradicating pharyngeal carriage 
of N. gonorrhoeae, which is an important component in the 
transmission of gonorrhoea in MSM. 
No confirmed cephalosporin-resistant gonococcal strains 
have been isolated to date. However, there are growing reports 
of N. gonorrhoeae isolates that exhibit reduced susceptibility 
to third-generation cephalosporins on in vitro testing. 
Some of these strains already exhibit significant resistance 
to other antibiotics.20  In central Japan, significant rises in 
gonococci exhibiting decreased susceptibility to penicillin, 
fluoroquinolones, tetracycline and oral cephalosporins have 
been observed since 2001.21  However, these strains have 
remained susceptible to ceftriaxone and spectinomycin. Within 
Japan, intramuscular ceftriaxone is therefore recommended 
in preference to oral cephalosporins for the treatment of 
antibiotic-resistant gonorrhoea.
Transformation of a cefixime-susceptible recipient gonococcal 
strain with the penicillin-binding protein-2 (PBP-2) gene 
(penA) amplified from a strain with reduced susceptibility 
for cefixime (MIC = 0.5 mg/l) resulted in development 
of resistance to cefixime and penicillin.22  Sequencing the 
penA gene in gonococci exhibiting reduced susceptibility to 
cefixime revealed a mosaic-like structure of PBP-2, in which 
some regions showed homology to penA genes in N. perflava 
(N. sicca), N. cinerea, N. flavescens and N. meningitidis. The 
mechanism of reduced susceptibility to cefixime and penicillin 
thus appears similar to that observed in meningococci and 
Streptococcus pneumoniae. Recent sequencing data of the 
ponA gene, which encodes for PBP-1, in gonococci exhibiting 
decreased susceptibility to cefixime has also identified an 
additional mutation, namely the replacement of leucine 421 by 
proline, although the presence of the mosaic PBP-2 was still 
thought to be the major factor accounting for the observed 
reduced susceptibility phenotype.23      
Antibiotic-resistant gonorrhoea –  
issues for South Africa
South Africa has followed the syndromic management 
approach, as advocated by the WHO, for over a decade. 
Within the STI treatment algorithms, a single 500 mg dose 
Fig. 1. Prevalence of ciprofloxacin resistance (%) in six South African 
cities as determined by the 2004 National Surveillance Study.19
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ciprofloxacin is the therapeutic agent used to treat presumptive 
gonorrhoea. In addition, 1-week courses of doxycycline or 
erythromycin (pregnant women) are co-administered to 
treat potential chlamydial disease in uncomplicated male 
urethritis and vaginal discharge syndromes. In those few 
patients infected with tetracycline- or erythromycin-susceptible 
N. gonorrhoeae strains, these latter agents may treat any 
gonorrhoea present even if the gonococci are resistant to 
ciprofloxacin.
Given the current prevalence of QRNG in South Africa’s 
major cities, it is clear that ciprofloxacin can no longer be 
relied upon to cure gonococcal infections. Inadequately treated 
gonococcal infections will lead to loss of confidence in the 
public health service by patients who fail to improve after 
therapy, to increased complications such as epididymo-orchitis 
and pelvic inflammatory disease, to increased prevalence 
of ciprofloxacin-resistant gonococci in the community and, 
perhaps of greatest concern for a country already over-
burdened with large numbers of people living with HIV/AIDS, 
new cases of HIV infection. Studies from Malawi have clearly 
demonstrated that the HIV-1 viral load in semen of men with 
acute urethritis is about eight times higher than in dermatology 
control patients.24  Even with the administration of effective 
antimicrobial treatment for gonorrhoea at the start, it takes 
more than 2 weeks for the HIV-1 seminal viral load to decrease 
to a level comparable with that in a non-STI control population. 
To date, there has been no laboratory-confirmed ceftriaxone- 
or cefixime-resistant N. gonorrhoeae strain isolated in South 
Africa. The only antibiotic available on the country’s Essential 
Drugs List that can reliably treat gonococcal infections in 2007 
is ceftriaxone, and a decision to make ceftriaxone 250 mg 
IM stat. the first-line therapy in the syndromic management 
algorithms is urgently needed. Given the large number of STI 
syndromes treated each year in South Africa’s public health 
sector, the use of ceftriaxone will not be without operational 
challenges including increasing the workload of nurses and a 
likely rise in the number of occupational needlestick injuries. In 
addition, the painful nature of ceftriaxone injections may deter 
some patients and their partners from attending for future 
STI treatment. Cefixime 400 mg as a single oral dose offers an 
attractive alternative, but there are some concerns about the 
emergence of cefixime treatment failure in the future. Cefixime 
is not currently available in South Africa; co-ordinated action 
is needed to either resume manufacture this drug within the 
country or to obtain it from an outside source.
The future
It is clear that a new class of therapeutic agent active against 
the gonococcus is urgently needed but there are no obvious 
candidates at present. Multidrug therapy will be the likely way 
forward in the foreseeable future. Synergistic combinations 
of antimicrobials would be a bonus and, in this regard, recent 
in vitro data suggest that cefixime and azithromycin could 
potentially be synergistic in vivo.25  While we struggle to 
find more effective antimicrobial agents to fight gonococcal 
infections, one must not forget the importance of focusing on 
STI prevention efforts through increased education around, 
and better social marketing of, condoms which provide cheap 
and effective ways to avoid gonorrhoea. 
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